Local lymph node assay (LLNA) for detection of sensitization capacity of chemicals.
The local lymph node assay (LLNA) is a murine model developed to evaluate the skin sensitization potential of chemicals. The LLNA is an alternative approach to traditional guinea pig methods and in comparison provides important animal welfare benefits. The assay relies on measurement of events induced during the induction phase of skin sensitization, specifically lymphocyte proliferation in the draining lymph nodes which is a hallmark of a skin sensitization response. Since its introduction the LLNA has been the subject of extensive evaluation on a national and international scale, and has been successfully validated and incorporated worldwide into regulatory guidelines. Experience gained in recent years has demonstrated that adherence to published procedures and guidelines for the LLNA (e.g., with respect to dose and vehicle selection) is critical for the successful conduct and eventual interpretation of the data. In addition to providing a robust method for skin sensitization hazard identification, the LLNA has proven very useful in assessing the skin sensitizing potency of test chemicals, and this has provided invaluable information to risk assessors. The primary method to make comparisons of the relative potency of chemical sensitizers is to use linear interpolation to estimate the concentration of chemical required to induce a stimulation index of three relative to concurrent vehicle-treated controls (EC3). In certain situations where there are available less than optimal dose response data a log-linear extrapolation method can be used to estimate an EC3 value which can reduce significantly the need for repeat testing of chemicals. The LLNA, when conducted according to published guidelines, provides a robust method for skin sensitization testing that not only provides reliable hazard identification information but also data necessary for effective risk assessment and risk management.
Gerberick
G Frank
GF
The Procter & Gamble Company, Central Product Safety Department, Miami Valley Innovation Center, P.O. Box 538707, Cincinnati, OH 45253, USA. gerberick.gf@pg.com
Ryan
Cindy A
CA
Dearman
Rebecca J
RJ
Kimber
Ian
I
D000818:Animals; D017449:Dermatitis, Allergic Contact / Q000276:immunology / Q000473:pathology*; D004195:Disease Models, Animal; D007509:Irritants / Q000276:immunology / Q000633:toxicity*; D023441:Local Lymph Node Assay; D051379:Mice; D008808:Mice, Inbred CBA; D018675:Toxicity Tests
D007509:Irritants